Signaling by the tumor-suppressor protein p53 antagonizes CRISPR–Cas9 gene editing of human pluripotent stem cells and immortalized human retinal pigment epithelial cells.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia
Journal of Hematology & Oncology Open Access 14 February 2019
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Urnov, F. D. CRISPR J. 1, 34–46 (2018).
Doudna, J. A. & Charpentier, E. Science 346, 1258096–1258096 (2014).
Hockemeyer, D. & Jaenisch, R. Cell Stem Cell 18, 573–586 (2016).
Ihry, R. J. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0050-6 (2018).
Haapaniemi, E. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0049-z (2018).
Meyers, R. M. et al. Nat. Genet. 49, 1779–1784 (2017).
Tebas, P. et al. N. Engl. J. Med. 370, 901–910 (2014).
Qasim, W. et al. Sci. Transl. Med. 9, eaaj2013 (2017).
Urnov, F. D. Curr. Opin. Genet. Dev. 52, 48–56 (2018).
Schwartz, S. D. et al. Lancet 385, 509–516 (2015).
da Cruz, L. et al. Nat. Biotechnol. 36, 328–337 (2018).
Dunbar, C. E. et al. Science 359, eaan4672 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Urnov, F.D. A path to efficient gene editing. Nat Med 24, 899–900 (2018). https://doi.org/10.1038/s41591-018-0110-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-018-0110-y
This article is cited by
-
Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia
Journal of Hematology & Oncology (2019)